Press Releases
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
Corbus Pharmaceuticals Announces Adjournment of Annual Meeting
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
